Latest Insider Transactions at Alnylam Pharmaceuticals, Inc. (ALNY)
This section provides a real-time view of insider transactions for Alnylam Pharmaceuticals, Inc. (ALNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALNYLAM PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALNYLAM PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,752
-1.49%
|
$439,752
$251.62 P/Share
|
|
Nov 27
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,531
-2.75%
|
$385,812
$252.59 P/Share
|
|
Nov 26
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,469
-1.9%
|
$367,250
$250.35 P/Share
|
|
Nov 26
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,469
-2.07%
|
$367,250
$250.35 P/Share
|
|
Nov 26
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,682
-1.06%
|
$420,500
$250.35 P/Share
|
|
Nov 26
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,682
-1.81%
|
$420,500
$250.35 P/Share
|
|
Nov 26
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,219
-1.27%
|
$1,304,750
$250.35 P/Share
|
|
Nov 25
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+15.89%
|
-
|
|
Nov 25
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.99%
|
-
|
|
Nov 25
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,434
+9.6%
|
-
|
|
Nov 25
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
3,434
+15.21%
|
-
|
|
Nov 25
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,658
+11.25%
|
-
|
|
Oct 08
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
96
+0.61%
|
-
|
|
Oct 01
2024
|
Robert W. Hesslein EVP, CLO and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,245
+50.0%
|
-
|
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-16.96%
|
$4,200,000
$280.0 P/Share
|
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+14.5%
|
$1,275,000
$85.0 P/Share
|
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
22,025
-14.64%
|
$5,968,775
$271.83 P/Share
|
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
20,725
+26.47%
|
$1,885,975
$91.36 P/Share
|
|
Aug 06
2024
|
Dennis A Ausiello Director |
SELL
Open market or private sale
|
Direct |
20,250
-46.12%
|
$5,305,500
$262.79 P/Share
|
|
Aug 06
2024
|
Dennis A Ausiello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,250
+40.16%
|
$2,389,500
$118.24 P/Share
|
|
Aug 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,148
-17.1%
|
$4,089,960
$270.0 P/Share
|
|
Aug 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,148
+14.6%
|
$1,287,580
$85.0 P/Share
|
|
Jul 11
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,093
-8.81%
|
$1,851,273
$261.0 P/Share
|
|
Jun 25
2024
|
Amy W Schulman Director |
SELL
Open market or private sale
|
Direct |
8,500
-50.19%
|
$2,040,000
$240.0 P/Share
|
|
Jun 25
2024
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+33.42%
|
$1,113,500
$131.21 P/Share
|
|
Jun 25
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,198
-0.67%
|
$274,342
$229.42 P/Share
|
|
Jun 25
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,605
-1.07%
|
$367,545
$229.42 P/Share
|
|
Jun 25
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,605
-0.45%
|
$367,545
$229.42 P/Share
|
|
Jun 25
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,301
-0.81%
|
$1,900,929
$229.42 P/Share
|
|
Jun 25
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
2,103
-1.05%
|
$481,587
$229.42 P/Share
|
|
Jun 24
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,498
+13.97%
|
-
|
|
Jun 24
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+19.82%
|
-
|
|
Jun 24
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+9.71%
|
-
|
|
Jun 24
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,953
+16.03%
|
-
|
|
Jun 24
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,295
+19.52%
|
-
|
|
Jun 24
2024
|
David E I Pyott Director |
SELL
Open market or private sale
|
Direct |
32,450
-67.16%
|
$7,171,450
$221.0 P/Share
|
|
Jun 24
2024
|
David E I Pyott Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,450
+30.42%
|
$2,498,650
$77.05 P/Share
|
|
May 29
2024
|
Amy W Schulman Director |
SELL
Open market or private sale
|
Direct |
21,700
-30.62%
|
$3,211,600
$148.97 P/Share
|
|
May 29
2024
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+49.89%
|
$1,980,000
$66.83 P/Share
|
|
Mar 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,754
+24.84%
|
-
|
|
Mar 01
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,741
+22.14%
|
-
|
|
Mar 01
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+26.15%
|
-
|
|
Mar 01
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+32.24%
|
-
|
|
Feb 29
2024
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
30,000
-56.94%
|
$4,590,000
$153.11 P/Share
|
|
Feb 29
2024
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$1,770,000
$59.25 P/Share
|
|
Feb 28
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
SELL
Open market or private sale
|
Direct |
329
-1.51%
|
$51,324
$156.35 P/Share
|
|
Feb 28
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
501
-1.8%
|
$78,156
$156.35 P/Share
|
|
Feb 28
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
574
-1.27%
|
$89,544
$156.35 P/Share
|
|
Feb 28
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,932
-1.17%
|
$457,392
$156.35 P/Share
|
|
Feb 28
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
574
-0.58%
|
$89,544
$156.35 P/Share
|